Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05986682 · OUTCOME

Sources of Distress Using NCCN DT: Top 5 Most Frequently Reported Problems

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2025-02-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_UNITS
Unit
Visits
Interval / dispersion
Not reported
Time frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

What was measured

Sources of distress will be assessed using the NCCN DT Problem List by examining the percentage of visits where types of problems are reported. The problem list includes 39 possible problems from which patients can choose. The problems are reported as a number and % of the total number of visits where problem lists are reported.

Groups in this outcome

Multiple Myeloma/Blenrep Participants

Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Multiple Myeloma/Blenrep Participants30

Analysis denominator · Visits

GroupSource count
Multiple Myeloma/Blenrep Participants209

Reported measurements

Fatigue
Values in Visits · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants69Not reportedNot reportedNot reportedNot reported
Pain
Values in Visits · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants63Not reportedNot reportedNot reportedNot reported
Tingling in Hands/Feet
Values in Visits · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants40Not reportedNot reportedNot reportedNot reported
Worry
Values in Visits · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants33Not reportedNot reportedNot reportedNot reported
Getting Around
Values in Visits · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants31Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        69
    title
    Fatigue
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        63
    title
    Pain
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        40
    title
    Tingling in Hands/Feet
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        33
    title
    Worry
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        31
    title
    Getting Around
denom Units Selected
Visits
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
  2. counts
    1. group Id
      OG000
      value
      209
    units
    Visits
description
Sources of distress will be assessed using the NCCN DT Problem List by examining the percentage of visits where types of problems are reported. The problem list includes 39 possible problems from which patients can choose. The problems are reported as a number and % of the total number of visits where problem lists are reported.
groups
  1. description
    Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023
    id
    OG000
    title
    Multiple Myeloma/Blenrep Participants
param Type
COUNT_OF_UNITS
reporting Status
POSTED
time Frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
title
Sources of Distress Using NCCN DT: Top 5 Most Frequently Reported Problems
type
SECONDARY
type Units Analyzed
Visits
unit Of Measure
Visits

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice